Antekang Cheng Biotechnology closes multimillion-yuan Series A round

Antekang Cheng Biotechnology, a Chinese tumor EFT technology research and development company, announced the completion of its Series A financing round on July 1. The round was led by Yuansheng Venture Capital and joined by Furong Capital.

Antekang Cheng Biotechnology, a Chinese tumor EFT technology research and development company, announced the completion of its Series A financing round on July 1. The round was led by Yuansheng Venture Capital and joined by Furong Capital.

Proceeds from this round of financing will be used to promote the clinical trials of the company’s glioblastoma electric field therapy products and the registration of related products.

Founded in 2017, Antekang Cheng Biotechnology is a developer of alternating electric field therapy, also known as tumor treating fields intended to treat glioblastoma multiforme.

The company accomplished the visualization of intracranial field strength, and is able to track the tumor within the field strength by managing the electro-nodes.

The company has also developed precision medical system based on biophysical model and multimodality image fusion system.

Currently, the company has initiated clinical trial studies on glioblastoma. The company has also cooperated with relevant clinical experts to conduct clinical studies on other solid tumors.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/03/antekang-cheng-biotechnology-closes-multimillion-yuan-series-a-round/.

Leave a Reply

Please Login to Comment